Altogether, regarding the low cost of FACS analysis (~14$ per biopsy sample), HX103-based FACS may serve as a cost-effective test in precision medicine trials to stratify NSCLC patients for EGFR-TKI treatment. Here, EGFR is linked to non-small cell lung carcinoma.